Results 301 to 310 of about 411,227 (332)
Some of the next articles are maybe not open access.
Biochemical Society Transactions, 1992
Current research into antibody engineering stresses the design of constructs that have both scientific and medical significance. Highlights of the past year include several successful humanizations of non-human antibodies, in which a human antibody is created that possesses the same binding specificity as the non-human one, and phage display of ...
openaire +5 more sources
Current research into antibody engineering stresses the design of constructs that have both scientific and medical significance. Highlights of the past year include several successful humanizations of non-human antibodies, in which a human antibody is created that possesses the same binding specificity as the non-human one, and phage display of ...
openaire +5 more sources
Engineering Antibodies for Therapy
Immunological Reviews, 1992Success in the generation of an antibody-based therapeutic requires careful consideration of the binding site, to achieve specificity and high affinity; of the effector, to produce the desired therapeutic effect; of the means of attachment of the effector to the binding site; production of the end product; and the response made by the patient to the ...
A, Mountain, J R, Adair
openaire +5 more sources
Engineering Antibodies for the Clinic
Cancer and Metastasis Reviews, 1999In the last ten years recombinant 'protein drugs' such as erythropoietin or tissue plasminogen activator have become widely used in the clinic. After some early setbacks antibodies look well placed to join them. A decade of antibody engineering is finally beginning to pay off with a string of chimeric and humanized antibodies gaining the Food and Drug ...
Philipp Holliger, Heribert Bohlen
openaire +3 more sources
Endeavour, 1994
A century ago, in his private laboratory in Berlin, Paul Ehrlich conceived and developed the idea of using antibodies to target toxic molecules. Recent advances in genetic engineering have enormously extended the potential of this concept for the treatment of malignant diseases, by making it possible to isolate genes encoded for the antibody variable ...
openaire +2 more sources
A century ago, in his private laboratory in Berlin, Paul Ehrlich conceived and developed the idea of using antibodies to target toxic molecules. Recent advances in genetic engineering have enormously extended the potential of this concept for the treatment of malignant diseases, by making it possible to isolate genes encoded for the antibody variable ...
openaire +2 more sources
Radioimmunotherapy with engineered antibodies
Expert Opinion on Biological Therapy, 2004Although the advent of monoclonal antibody technology in the 1970s provided the means to specifically target radioisotopes to tumours, the initial clinical evaluations of radioimmunotherapy (RAIT) were largely unsuccessful. Over the past few decades, molecular biology techniques have advanced sufficiently to allow scientists to re-engineer antibodies ...
Maria Russeva, Gregory P. Adams
openaire +3 more sources
Biotechnology and Bioprocess Engineering, 2002
Monoclonal antibodies (Mabs) have been used as diagnostic and analytical reagents since hybridoma technology was invented in 1975. In recent years, antibodies have become increasingly accepted as therapeutics for human diseases, particularly for cancer, viral infection and autoimmune disorders.
Sun Taek Kim, Hyo Jeong Hong
openaire +2 more sources
Monoclonal antibodies (Mabs) have been used as diagnostic and analytical reagents since hybridoma technology was invented in 1975. In recent years, antibodies have become increasingly accepted as therapeutics for human diseases, particularly for cancer, viral infection and autoimmune disorders.
Sun Taek Kim, Hyo Jeong Hong
openaire +2 more sources
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
Philipp Holliger, Greg Winter
openaire +3 more sources
Current Opinion in Biotechnology, 1991
Antibody engineering has received a boost from the development of an Escherichia coli expression system that now allows the screening of libraries with bacteria or phages. These random selection techniques can be applied using knowledge obtained from new X-ray structures of recombinant antibody domains, and anti-peptide antibodies.
openaire +2 more sources
Antibody engineering has received a boost from the development of an Escherichia coli expression system that now allows the screening of libraries with bacteria or phages. These random selection techniques can be applied using knowledge obtained from new X-ray structures of recombinant antibody domains, and anti-peptide antibodies.
openaire +2 more sources
Current Opinion in Structural Biology, 1995
Antibody engineering has been an extremely intensive research area for many years. Recent achievements discussed in this review include: (i) significant improvements in the field of selection of antigen-specific antibody fragments on bacteriophages; (ii) new structural work, in particular using NMR; (iii) the cloning of essentially the complete set of ...
openaire +2 more sources
Antibody engineering has been an extremely intensive research area for many years. Recent achievements discussed in this review include: (i) significant improvements in the field of selection of antigen-specific antibody fragments on bacteriophages; (ii) new structural work, in particular using NMR; (iii) the cloning of essentially the complete set of ...
openaire +2 more sources
Immunogenicity of engineered antibodies
Methods, 2005Administration of a therapeutic antibody can lead to an anti-antibody response (AAR). Much effort has been applied to engineering antibodies with as little as possible non-human structure to minimize such responses. Here, we review reported AAR to murine, mouse-human chimeric, and humanized antibodies.
Jefferson Foote, William Hwang
openaire +3 more sources